Charles River Laboratories International Inc.
Charles River Laboratories International Inc., founded in 1947 and headquartered in Wilmington, Massachusetts, United States, is a premier contract research organization providing comprehensive…
Snapshot
Charles River Laboratories International Inc. is a life sciences tools and services company that has completed 23 disclosed acquisitions and reported $4.02B in latest-year revenue.
- Sector
- Life Sciences Tools and Services
- Ticker
- CRL
- Revenue (LTM)
- $4.02B
- Acquisitions
- 23
- Operating margin
- 0.6%
- Latest call
- Q1 2026
Business description
Charles River Laboratories International Inc., founded in 1947 and headquartered in Wilmington, Massachusetts, United States, is a premier contract research organization providing comprehensive preclinical and clinical laboratory services. The company’s flagship offerings include in vivo and in vitro testing, toxicology studies, and integrated preclinical development solutions under its CRL Discovery Services. Under the leadership of CEO James C. Foster since 2017, CRL has secured a leading position in the global CRO market with an estimated 15% market share in its preclinical segment. Focused on digital transformation and strategic growth initiatives, the company is poised to achieve an anticipated annual revenue growth of 8-10%.
Everything on Charles River Laboratories International Inc.
Financials
Leadership & board
Acquisitions
Share repurchases
On October 29, 2025, the Board approved a new $1.0 billion stock repurchase authorization replacing the prior $1.0 billion program; the company repurchased 2.1 million shares for $350.0 million in fiscal 2025 and had $1.0 billion remaining as of December 27, 2025.
Competition & customers
No single client accounted for more than 4% of revenue in fiscal years 2025, 2024, or 2023, or trade receivables as of December 27, 2025 or December 28, 2024.